MARKET

FBLG

FBLG

Fibrobiologics
NASDAQ
0.3237
-0.0202
-5.87%
Opening 11:56 01/08 EST
OPEN
0.3484
PREV CLOSE
0.3439
HIGH
0.3500
LOW
0.3092
VOLUME
1.63M
TURNOVER
--
52 WEEK HIGH
2.335
52 WEEK LOW
0.2201
MARKET CAP
21.53M
P/E (TTM)
-0.6731
1D
5D
1M
3M
1Y
5Y
1D
FibroBiologics CEO says 2026 ‘will be about execution’
TipRanks · 1d ago
FibroBiologics Is Maintained at Buy by D. Boral Capital
Dow Jones · 2d ago
FibroBiologics Price Target Maintained With a $15.00/Share by D. Boral Capital
Dow Jones · 2d ago
D. Boral Capital Maintains Buy on FibroBiologics, Maintains $15 Price Target
Benzinga · 2d ago
FibroBiologics CEO to Present at BFC Global Healthcare Business Development and Investment Conference
Reuters · 2d ago
FibroBiologics announces preclinical results for FSdC
TipRanks · 3d ago
FibroBiologics Reports Positive Preclinical Results for FSdC Therapy in Degenerative Disc Disease
Reuters · 3d ago
FIBROBIOLOGICS ANNOUNCES POSITIVE PRECLINICAL RESULTS FOR A FIBROBLAST SPHEROID-DERIVED CHONDROCYTE (FSDC) SPHEROID THERAPY FOR DEGENERATIVE DISC DISEASE
Reuters · 3d ago
More
About FBLG
FibroBiologics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing fibroblast-based therapies for patients suffering from chronic diseases with significant unmet medical needs, including wound healing, multiple sclerosis, degenerative disc disease, psoriasis and certain cancers, and potential human longevity applications including thymic involution reversal. Its product candidates include CybroCell, CYMS101 and CYWC628. CybroCell is an allogeneic fibroblast cell-based therapy for degenerative disc disease. This technology is being designed as an alternative method for repairing the cartilage of the intervertebral disc (or any other articular cartilage). It is developing CYMS101 as an allogeneic fibroblast cell-based therapy to treat multiple sclerosis (MS) and has completed the Phase I study. It is developing CYWC628 as an allogeneic fibroblast cell-based therapy for wound healing. Its CYPS317 is used for the treatment of Psoriasis.

Webull offers Fibrobiologics Inc stock information, including NASDAQ: FBLG real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FBLG stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FBLG stock methods without spending real money on the virtual paper trading platform.